BMS-188667 (CTLA4Ig)
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for BMS-188667 (CTLA4Ig), covering 2011-04-13 to 2011-06-23. Get the full timeline:
Most recent: Clinical Trial Update: Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past. [Phase 3]